BEIJING (Reuters) – China’s Shanghai Fosun Pharmaceutical Group said on Thursday an experimental antibody treatment for COVID-19 being developed by its unit had been approved for human testing in the United States and the trial was expected to start soon.
Several drugmakers are testing antibody treatments for COVID-19 to help patients’ immune systems fight the coronavirus that causes the disease which has killed over 1 million people worldwide.
Health experts say such antibody treatments could be used as a therapeutic bridge until vaccines become widely available.
Fosun said its unit, Hengenix Biotech Inc, planned to start an early stage clinical trial in the United States “in the near future after conditions are ready.”
Hengenix’s HLX70, a monoclonal neutralising antibody treatment, has obtained a clinical trial approval from U.S.